BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene. 2006;25:3866-3884. [PMID: 16799628 DOI: 10.1038/sj.onc.1209550] [Cited by in Crossref: 269] [Cited by in F6Publishing: 260] [Article Influence: 16.8] [Reference Citation Analysis]
Number Citing Articles
1 Welker MW, Trojan J. Anti-angiogenesis in hepatocellular carcinoma treatment: Current evidence and future perspectives. World J Gastroenterol 2011; 17(26): 3075-3081 [PMID: 21912449 DOI: 10.3748/wjg.v17.i26.3075] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
2 Dimri M, Satyanarayana A. Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E491. [PMID: 32093152 DOI: 10.3390/cancers12020491] [Cited by in F6Publishing: 48] [Reference Citation Analysis]
3 Zamboni CG, Kozielski KL, Vaughan HJ, Nakata MM, Kim J, Higgins LJ, Pomper MG, Green JJ. Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma. J Control Release 2017;263:18-28. [PMID: 28351668 DOI: 10.1016/j.jconrel.2017.03.384] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 6.4] [Reference Citation Analysis]
4 Yang Y, Chang S, Zhao Z, Hou NI, He K, Wang X, Gao L, Wang L, Cai D, Guo BO, Tong D, Song T, Huang C. MicroRNA-214 suppresses the proliferation of human hepatocellular carcinoma cells by targeting E2F3. Oncol Lett 2015;10:3779-84. [PMID: 26788207 DOI: 10.3892/ol.2015.3745] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
5 Shu G, Xie B, Ren F, Liu D, Zhou J, Li Q, Chen J, Yuan L, Zhou J. Restoration of klotho expression induces apoptosis and autophagy in hepatocellular carcinoma cells. Cell Oncol 2013;36:121-9. [DOI: 10.1007/s13402-012-0118-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
6 Höpfner M, Schuppan D, Scherübl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008; 14(1): 1-14 [PMID: 18176955 DOI: 10.3748/wjg.14.1] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 74] [Article Influence: 5.1] [Reference Citation Analysis]
7 Yang H, Bushue N, Bu P, Wan YJ. Induction and intracellular localization of Nur77 dictate fenretinide-induced apoptosis of human liver cancer cells. Biochem Pharmacol 2010;79:948-54. [PMID: 19912993 DOI: 10.1016/j.bcp.2009.11.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
8 Schulze-Bergkamen H, Fleischer B, Schuchmann M, Weber A, Weinmann A, Krammer PH, Galle PR. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. BMC Cancer 2006;6:232. [PMID: 17014711 DOI: 10.1186/1471-2407-6-232] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 4.4] [Reference Citation Analysis]
9 Martín-Sanz P, Casado M, Boscá L. Cyclooxygenase 2 in liver dysfunction and carcinogenesis: Facts and perspectives. World J Gastroenterol 2017; 23(20): 3572-3580 [PMID: 28611510 DOI: 10.3748/wjg.v23.i20.3572] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
10 Kim HS, Jung G. Notch1 increases Snail expression under high reactive oxygen species conditions in hepatocellular carcinoma cells. Free Radic Res 2014;48:806-13. [PMID: 24684482 DOI: 10.3109/10715762.2014.909595] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
11 Lai JP, Thompson JR, Sandhu DS, Roberts LR. Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets. Future Oncol. 2008;4:803-814. [PMID: 19086847 DOI: 10.2217/14796694.4.6.803] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
12 Ma Y, Xu YC, Tang L, Zhang Z, Wang J, Wang HX. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol. 2012;1:11. [PMID: 23210562 DOI: 10.1186/2162-3619-1-11] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 5.5] [Reference Citation Analysis]
13 Carbajo-pescador S, Martín-renedo J, García-palomo A, Tuñón MJ, Mauriz JL, González-gallego J. Changes in the expression of melatonin receptors induced by melatonin treatment in hepatocarcinoma HepG2 cells. Journal of Pineal Research 2009;47:330-8. [DOI: 10.1111/j.1600-079x.2009.00719.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
14 Ho JC, Ip YC, Cheung ST, Lee YT, Chan KF, Wong SY, Fan ST. Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology 2008;47:1524-32. [PMID: 18393387 DOI: 10.1002/hep.22191] [Cited by in Crossref: 84] [Cited by in F6Publishing: 86] [Article Influence: 6.0] [Reference Citation Analysis]
15 Buendia MA. Tumor suppressors in hepatocellular carcinoma: many are called, but few are chosen. J Hepatol 2007;46:546-8. [PMID: 17313992 DOI: 10.1016/j.jhep.2007.01.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
16 Wang Y, Sun Z, Peng J, Zhan L. Bioluminescent imaging of hepatocellular carcinoma in live mice. Biotechnol Lett 2007;29:1665-70. [PMID: 17609854 DOI: 10.1007/s10529-007-9452-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
17 Zhong C, Qiu S, Li J, Shen J, Zu Y, Shi J, Sui G. Ellagic acid synergistically potentiates inhibitory activities of chemotherapeutic agents to human hepatocellular carcinoma. Phytomedicine 2019;59:152921. [PMID: 31055231 DOI: 10.1016/j.phymed.2019.152921] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
18 Rajendran P, Li F, Manu KA, Shanmugam MK, Loo SY, Kumar AP, Sethi G. γ-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent. Br J Pharmacol. 2011;163:283-298. [PMID: 21198544 DOI: 10.1111/j.1476-5381.2010.01187.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 84] [Article Influence: 8.5] [Reference Citation Analysis]
19 Chang Q, Chen J, Beezhold KJ, Castranova V, Shi X, Chen F. JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma. Mol Cancer 2009;8:64. [PMID: 19686584 DOI: 10.1186/1476-4598-8-64] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
20 Liang C, Zhang B, Ge H, Xu Y, Li G, Wu J. Long non-coding RNA CRNDE as a potential prognostic biomarker in solid tumors: A meta-analysis. Clin Chim Acta 2018;481:99-107. [PMID: 29501692 DOI: 10.1016/j.cca.2018.02.039] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
21 Abou El Naga RN, Azab SS, El-demerdash E, Shaarawy S, El-merzabani M, Ammar EM. Sensitization of TRAIL-induced apoptosis in human hepatocellular carcinoma HepG2 cells by phytochemicals. Life Sciences 2013;92:555-61. [DOI: 10.1016/j.lfs.2013.01.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
22 Naboulsi W, Megger DA, Bracht T, Kohl M, Turewicz M, Eisenacher M, Voss DM, Schlaak JF, Hoffmann A, Weber F, Baba HA, Meyer HE, Sitek B. Quantitative Tissue Proteomics Analysis Reveals Versican as Potential Biomarker for Early-Stage Hepatocellular Carcinoma. J Proteome Res 2016;15:38-47. [DOI: 10.1021/acs.jproteome.5b00420] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
23 Hervé J, Cunha AS, Liu B, Valogne Y, Longuet M, Boisgard R, Brégerie O, Roux J, Guettier C, Calès P. Internal radiotherapy of liver cancer with rat hepatocarcinoma-intestine-pancreas gene as a liver tumor-specific promoter. Hum Gene Ther. 2008;19:915-926. [PMID: 18759560 DOI: 10.1089/hum.2007.153] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
24 Lu J, Hsia Y, Tu H, Hsiao Y, Yang W, Wang H, Yuh C. Liver development and cancer formation in zebrafish. Birth Defects Research Part C: Embryo Today: Reviews 2011;93:157-72. [DOI: 10.1002/bdrc.20205] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
25 Bishayee A. The role of inflammation and liver cancer. Adv Exp Med Biol. 2014;816:401-435. [PMID: 24818732 DOI: 10.1007/978-3-0348-0837-8_16] [Cited by in Crossref: 130] [Cited by in F6Publishing: 123] [Article Influence: 16.3] [Reference Citation Analysis]
26 Liu YJ, Chen FH, Su CQ, Wang XH, Qian YZ, Qian QJ. A novel oncolytic adenovirus carrying human tumor necrosis factor-related apoptosis-inducing ligand gene induces hepatocellular carcinoma cell line apoptosis in vitro. Shijie Huaren Xiaohua Zazhi 2009; 17(3): 241-246 [DOI: 10.11569/wcjd.v17.i3.241] [Reference Citation Analysis]
27 Li L, Dai H, Yeh F, Kan S, Lang J, Hsu JL, Jeng L, Chen Y, Sher Y, Lin W, Hung M. Targeted hepatocellular carcinoma proapoptotic BikDD gene therapy. Oncogene 2011;30:1773-83. [DOI: 10.1038/onc.2010.558] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
28 Clément S, Peyrou M, Sanchez-pareja A, Bourgoin L, Ramadori P, Suter D, Vinciguerra M, Guilloux K, Pascarella S, Rubbia-brandt L, Negro F, Foti M. Down-regulation of phosphatase and tensin homolog by hepatitis C virus core 3a in hepatocytes triggers the formation of large lipid droplets. Hepatology 2011;54:38-49. [DOI: 10.1002/hep.24340] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]
29 Hui D, Qiang L, Jian W, Ti Z, Da-Lu K. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis. 2009;41:36-41. [PMID: 18818130 DOI: 10.1016/j.dld.2008.04.007] [Cited by in Crossref: 97] [Cited by in F6Publishing: 101] [Article Influence: 6.9] [Reference Citation Analysis]
30 Xue Y, Yang G, Wang C, Li X, Du G. Effects of shRNA-Mediated SOX9 Inhibition on Cell Proliferation and Apoptosis in Human HCC Cell Line Hep3B Mediated by Ultrasound-Targeted Microbubble Destruction (UTMD). Cell Biochem Biophys 2015;73:553-8. [PMID: 27352352 DOI: 10.1007/s12013-015-0685-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
31 Yu L, Wang Z, Mo Z, Zou B, Yang Y, Sun R, Ma W, Yu M, Zhang S, Yu Z. Synergetic delivery of triptolide and Ce6 with light-activatable liposomes for efficient hepatocellular carcinoma therapy. Acta Pharm Sin B 2021;11:2004-15. [PMID: 34386334 DOI: 10.1016/j.apsb.2021.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
32 Berasain C, Castillo J, Prieto J, Avila MA. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int 2007;27:174-85. [PMID: 17311611 DOI: 10.1111/j.1478-3231.2006.01424.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
33 Varshosaz J, Hassanzadeh F, Sadeghi H, Ghelich Khan Z, Rostami M. Retinoic Acid Decorated Albumin-Chitosan Nanoparticles for Targeted Delivery of Doxorubicin Hydrochloride in Hepatocellular Carcinoma. Journal of Nanomaterials 2013;2013:1-12. [DOI: 10.1155/2013/254127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
34 Rajiu V, Balaji P, Sheena TS, Akbarsha MA, Jeganathan K. Doxorubicin-Anchored Curcumin Nanoparticles for Multimode Cancer Treatment against Human Liver Carcinoma Cells. Part Part Syst Charact 2015;32:1028-42. [DOI: 10.1002/ppsc.201500098] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
35 Shim JH, Park J, Nam BH, Lee WJ, Kim C. Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 2009;63:459-67. [DOI: 10.1007/s00280-008-0759-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
36 Yan F, Wang XM, Pan C, Ma QM. Down-regulation of extracellular signal-regulated kinase 1/2 activity in P-glycoprotein-mediated multidrug resistant hepatocellular carcinoma cells. World J Gastroenterol 2009; 15(12): 1443-1451 [PMID: 19322916 DOI: 10.3748/wjg.15.1443] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
37 Peyrou M, Bourgoin L, Foti M. PTEN in liver diseases and cancer. World J Gastroenterol 2010; 16(37): 4627-4633 [PMID: 20872961 DOI: 10.3748/wjg.v16.i37.4627] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
38 Xu Y, Xia F, Ma L, Shan J, Shen J, Yang Z, Liu J, Cui Y, Bian X, Bie P, Qian C. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Letters 2011. [DOI: 10.1016/j.canlet.2011.06.027] [Cited by in Crossref: 22] [Cited by in F6Publishing: 93] [Article Influence: 2.0] [Reference Citation Analysis]
39 Jeong WJ, Park JC, Kim WS, Ro EJ, Jeon SH, Lee SK, Park YN, Min DS, Choi KY. WDR76 is a RAS binding protein that functions as a tumor suppressor via RAS degradation. Nat Commun 2019;10:295. [PMID: 30655611 DOI: 10.1038/s41467-018-08230-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
40 Song MA, Kwee SA, Tiirikainen M, Hernandez BY, Okimoto G, Tsai NC, Wong LL, Yu H. Comparison of genome-scale DNA methylation profiles in hepatocellular carcinoma by viral status. Epigenetics. 2016;11:464-474. [PMID: 27248055 DOI: 10.1080/15592294.2016.1151586] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
41 Avila MA, Lu KP. Hepatitis B Virus X Protein and Pin1 in Liver Cancer: “Les Liaisons Dangereuses”. Gastroenterology 2007;132:1180-3. [DOI: 10.1053/j.gastro.2007.01.061] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
42 Zerbini A, Pilli M, Fagnoni F, Pelosi G, Pizzi MG, Schivazappa S, Laccabue D, Cavallo C, Schianchi C, Ferrari C. Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation. J Immunother. 2008;31:271-282. [PMID: 18317360 DOI: 10.1097/cji.0b013e318160ff1c] [Cited by in Crossref: 45] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
43 Zhang F, Chen X, Xi K, Qiu Z, Wang Y, Gui Y, Hou Y, Chen K, Zhang X. Long noncoding RNA HOXD-AS1 in various cancers: a meta-analysis and TCGA data review. Onco Targets Ther 2018;11:7827-40. [PMID: 30464530 DOI: 10.2147/OTT.S184303] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
44 Liang C, Xu Y, Ge H, Li G, Wu J. Clinicopathological significance and prognostic role of p-STAT3 in patients with hepatocellular carcinoma. Onco Targets Ther 2018;11:1203-14. [PMID: 29551899 DOI: 10.2147/OTT.S156198] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
45 Yu R, Yang B, Chi X, Cai L, Liu C, Yang L, Wang X, He P, Lu X. Efficacy of cytokine-induced killer cell infusion as an adjuvant immunotherapy for hepatocellular carcinoma: a systematic review and meta-analysis. Drug Des Devel Ther. 2017;11:851-864. [PMID: 28360510 DOI: 10.2147/dddt.s124399] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
46 Zhang T, Li G, Li S, Wang Z, He D, Wang Y, Zhang J, Li J, Bai Z, Zhang Q, Liu B, Zhao Q, Liu Y, Zhang H. Asialoglycoprotein receptor targeted micelles containing carborane clusters for effective boron neutron capture therapy of hepatocellular carcinoma. Colloids and Surfaces B: Biointerfaces 2019;182:110397. [DOI: 10.1016/j.colsurfb.2019.110397] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
47 Liu ZC, Ning F, Wang HF, Chen DY, Cai YN, Sheng HY, Lash GE, Liu L, Du J. Epidermal growth factor and tumor necrosis factor α cooperatively promote the motility of hepatocellular carcinoma cell lines via synergistic induction of fibronectin by NF-κB/p65. Biochim Biophys Acta Gen Subj 2017;1861:2568-82. [PMID: 28844984 DOI: 10.1016/j.bbagen.2017.08.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
48 Patel P, Schutzer SE, Pyrsopoulos N. Immunobiology of hepatocarcinogenesis: Ways to go or almost there? World J Gastrointest Pathophysiol 2016; 7(3): 242-255 [PMID: 27574562 DOI: 10.4291/wjgp.v7.i3.242] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
49 Liang C, Xu Y, Li G, Zhao T, Xia F, Li G, Zhang D, Wu J. Downregulation of DcR3 sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis. Onco Targets Ther 2017;10:417-28. [PMID: 28176915 DOI: 10.2147/OTT.S127202] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
50 Li J, Liu D, Zhou D, Shao L, Chen X, Song H. Label-free photoelectrochemical biosensor for alpha-fetoprotein detection based on Au/CsxWO3 heterogeneous films. Talanta 2021;225:122074. [DOI: 10.1016/j.talanta.2020.122074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
51 Han CJ. Recent developments in systemic chemotherapy for hepatocellular carcinoma. Korean J Hepatol 2008;14:4. [DOI: 10.3350/kjhep.2008.14.1.4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
52 Liang C, Li W, Ge H, Zhang K, Li G, Wu J. Role of Beclin1 expression in patients with hepatocellular carcinoma: a meta-analysis. Onco Targets Ther 2018;11:2387-97. [PMID: 29740214 DOI: 10.2147/OTT.S151751] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
53 Subramaniam A, Loo SY, Rajendran P, Manu KA, Perumal E, Li F, Shanmugam MK, Siveen KS, Park JI, Ahn KS, Hui KM, Kumar AP, Sethi G. An anthraquinone derivative, emodin sensitizes hepatocellular carcinoma cells to TRAIL induced apoptosis through the induction of death receptors and downregulation of cell survival proteins. Apoptosis 2013;18:1175-87. [PMID: 23700228 DOI: 10.1007/s10495-013-0851-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
54 Welker MW, Lubomierski N, Gog C, Herrmann E, Engels K, Vogl TJ, Bechstein WO, Zeuzem S, Trojan J. Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions. J Chemother 2010;22:205-11. [PMID: 20566428 DOI: 10.1179/joc.2010.22.3.205] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
55 Akkiz H. The Emerging Role of MicroRNAs in Hepatocellular Carcinoma. Euroasian J Hepatogastroenterol 2014;4:45-50. [PMID: 29264318 DOI: 10.5005/jp-journals-10018-1095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
56 Tayel A, Abd El Galil KH, Ebrahim MA, Ibrahim AS, El-Gayar AM, Al-Gayyar MM. Suramin inhibits hepatic tissue damage in hepatocellular carcinoma through deactivation of heparanase enzyme. Eur J Pharmacol 2014;728:151-60. [PMID: 24530413 DOI: 10.1016/j.ejphar.2014.02.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
57 Zhang L, Yang L, Liu X, Chen W, Chang L, Chen L, Loera S, Chu P, Huang WC, Liu YR. MicroRNA-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin-like enhancer protein 1 through nuclear factor kappa B pathways. Hepatology. 2013;57:1919-1930. [PMID: 23175432 DOI: 10.1002/hep.26162] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
58 Liang C, Zhang Y, Zhang Y, Li R, Wang Z, Wei Z, Guo J. The prognostic value of LINC01296 in pan-cancers and the molecular regulatory mechanism in hepatocellular carcinoma: a comprehensive study based on data mining, bioinformatics, and in vitro validation. Onco Targets Ther 2019;12:5861-85. [PMID: 31410029 DOI: 10.2147/OTT.S205853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
59 Magalhães M, Farinha D, Pedroso de Lima MC, Faneca H. Increased gene delivery efficiency and specificity of a lipid-based nanosystem incorporating a glycolipid. Int J Nanomedicine 2014;9:4979-89. [PMID: 25368518 DOI: 10.2147/IJN.S69822] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
60 Kim YI, Chung JW. Selective or targeted gene/drug delivery for liver tumors: advantages and current status of local delivery. Expert Rev Gastroenterol Hepatol 2008;2:791-802. [PMID: 19090739 DOI: 10.1586/17474124.2.6.791] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
61 Su CL, Tseng CL, Ramesh C, Liu HS, Huang CF, Yao CF. Using gene expression database to uncover biology functions of 1,4-disubstituted 1,2,3-triazole analogues synthesized via a copper (I)-catalyzed reaction. Eur J Med Chem 2017;132:90-107. [PMID: 28342400 DOI: 10.1016/j.ejmech.2017.03.034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
62 Spahr N, Schilling P, Thoduka S, Abolmaali N, Schenk A. Predictive SIRT dosimetry based on a territorial model. EJNMMI Phys 2017;4:25. [PMID: 29090358 DOI: 10.1186/s40658-017-0192-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Peng N, He J, Li J, Huang H, Huang W, Liao Y, Zhu S. Long noncoding RNA MALAT1 inhibits the apoptosis and autophagy of hepatocellular carcinoma cell by targeting the microRNA-146a/PI3K/Akt/mTOR axis. Cancer Cell Int 2020;20:165. [PMID: 32435156 DOI: 10.1186/s12935-020-01231-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
64 Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol. 2010;52:594-604. [PMID: 20185200 DOI: 10.1016/j.jhep.2009.10.033] [Cited by in Crossref: 259] [Cited by in F6Publishing: 264] [Article Influence: 21.6] [Reference Citation Analysis]
65 Ji SP, Li Q, Dong H. Therapy and prognostic features of primary clear cell carcinoma of the liver. World J Gastroenterol 2010; 16(6): 764-769 [PMID: 20135727 DOI: 10.3748/wjg.v16.i6.764] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
66 Martínez-Chantar ML, Avila MA, Lu SC. Hepatocellular Carcinoma: Updates in Pathogenesis, Detection and Treatment. Cancers (Basel) 2020;12:E2729. [PMID: 32977536 DOI: 10.3390/cancers12102729] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Ueda S, Shirabe K, Morita K, Umeda K, Kayashima H, Uchiyama H, Soejima Y, Taketomi A, Maehara Y. Evaluation of ERCC1 Expression for Cisplatin Sensitivity in Human Hepatocellular Carcinoma. Ann Surg Oncol 2011;18:1204-11. [DOI: 10.1245/s10434-010-1414-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
68 Potenza N, Mosca N, Zappavigna S, Castiello F, Panella M, Ferri C, Vanacore D, Giordano A, Stiuso P, Caraglia M. MicroRNA-125a-5p Is a Downstream Effector of Sorafenib in Its Antiproliferative Activity Toward Human Hepatocellular Carcinoma Cells. J Cell Physiol. 2017;232:1907-1913. [PMID: 27982429 DOI: 10.1002/jcp.25744] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
69 Weber S, Jarnagin W, Duffy A, O'reilly EM, Abou-alfa GK, Blumgart L. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2008. pp. 1569-94. [DOI: 10.1016/b978-0-443-06694-8.50088-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
70 Pan K, Li YQ, Wang W, Xu L, Zhang YJ, Zheng HX, Zhao JJ, Qiu HJ, Weng DS, Li JJ, Wang QJ, Huang LX, He J, Chen SP, Ke ML, Wu PH, Chen MS, Li SP, Xia JC, Zeng YX. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol. 2013;20:4305-4311. [PMID: 23892527 DOI: 10.1245/s10434-013-3144-x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 6.1] [Reference Citation Analysis]
71 Liang C, Zhang K, Ge H, Li W, Li G, Wu J. Prognostic and clinicopathological value of Nanog in hepatocellular carcinoma: A meta-analysis. Clinica Chimica Acta 2018;477:24-31. [DOI: 10.1016/j.cca.2017.11.037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
72 Chan KM, Wu TH, Cheng CH, Lee CF, Wu TJ, Chou HS, Lee WC. Implementation of sorafenib treatment for advanced hepatocellular carcinoma: an illustration of current practice in Taiwan. Cancer Manag Res 2019;11:1013-21. [PMID: 30774429 DOI: 10.2147/CMAR.S186678] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
73 Li F, Fernandez PP, Rajendran P, Hui KM, Sethi G. Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett. 2010;292:197-207. [PMID: 20053498 DOI: 10.1016/j.canlet.2009.12.003] [Cited by in Crossref: 118] [Cited by in F6Publishing: 106] [Article Influence: 9.8] [Reference Citation Analysis]
74 Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34. [PMID: 19095497 DOI: 10.1016/s1470-2045(08)70285-7] [Cited by in Crossref: 3367] [Cited by in F6Publishing: 1875] [Article Influence: 240.5] [Reference Citation Analysis]
75 Zhou J, Chen L, Zhang Y, Wu Y, Wang G, He S, Guo Z, Wei Y. Synergistic effect of EMS1-shRNA and sorafenib on proliferation, migration, invasion and endocytosis of SMMC-7721. J Mol Histol 2014;45:205-16. [PMID: 24127012 DOI: 10.1007/s10735-013-9543-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
76 Kim JY, Kim EH, Park SS, Lim JH, Kwon TK, Choi KS. Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIP S down-regulation. J Cell Biochem 2008;105:1386-98. [DOI: 10.1002/jcb.21958] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 5.2] [Reference Citation Analysis]
77 Berasain C. New therapeutic targets in HCC: Reptin ATPase and HCC senescence. Journal of Hepatology 2010;52:633-4. [DOI: 10.1016/j.jhep.2010.01.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
78 Lim SO, Kim HS, Quan X, Ahn SM, Kim H, Hsieh D, Seong JK, Jung G. Notch1 binds and induces degradation of Snail in hepatocellular carcinoma. BMC Biol 2011;9:83. [PMID: 22128911 DOI: 10.1186/1741-7007-9-83] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
79 González A, Alonso-González C, González-González A, Menéndez-Menéndez J, Cos S, Martínez-Campa C. Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments. Cancers (Basel) 2021;13:3263. [PMID: 34209857 DOI: 10.3390/cancers13133263] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Kawashima M, Kohno R, Nakachi K, Nishio T, Mitsunaga S, Ikeda M, Konishi M, Takahashi S, Gotohda N, Arahira S. Dose-volume histogram analysis of the safety of proton beam therapy for unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011;79:1479-1486. [PMID: 20605350 DOI: 10.1016/j.ijrobp.2009.12.048] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
81 Yaghmai V, Besa C, Kim E, Gatlin JL, Siddiqui NA, Taouli B. Imaging Assessment of Hepatocellular Carcinoma Response to Locoregional and Systemic Therapy. American Journal of Roentgenology 2013;201:80-96. [DOI: 10.2214/ajr.13.10706] [Cited by in Crossref: 53] [Cited by in F6Publishing: 18] [Article Influence: 5.9] [Reference Citation Analysis]
82 Chang CM, Lo CH, Shih YM, Chen Y, Wu PY, Tsuneyama K, Roffler SR, Tao MH. Treatment of hepatocellular carcinoma with adeno-associated virus encoding interleukin-15 superagonist. Hum Gene Ther 2010;21:611-21. [PMID: 20064014 DOI: 10.1089/hum.2009.187] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
83 Long F, Dong C, Jiang K, Xu Y, Chi X, Sun D, Liang R, Gao Z, Shao S, Wang L. Melatonin enhances the anti-tumor effect of sorafenib via AKT/p27-mediated cell cycle arrest in hepatocarcinoma cell lines. RSC Adv 2017;7:21342-51. [DOI: 10.1039/c7ra02113e] [Cited by in Crossref: 9] [Article Influence: 1.8] [Reference Citation Analysis]
84 Xu C, Shi L, Chen W, Fang P, Li J, Jin L, Pan Z, Pan C. MiR-106b inhibitors sensitize TRAIL-induced apoptosis in hepatocellular carcinoma through increase of death receptor 4. Oncotarget 2017;8:41921-31. [PMID: 28410209 DOI: 10.18632/oncotarget.16707] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
85 Chen JL, Lao XM, Lin XJ, Xu L, Cui BK, Wang J, Lin GH, Shuang ZY, Mao YZ, Huang X, Yun JP, Jin JT, Li SP. Adjuvant Cytokine-Induced Killer Cell Therapy Improves Disease-Free and Overall Survival in Solitary and Nonmicrovascular Invasive Hepatocellular Carcinoma After Curative Resection. Medicine (Baltimore) 2016;95:e2665. [PMID: 26844496 DOI: 10.1097/MD.0000000000002665] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
86 Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer. 2007;43:979-992. [PMID: 17291746 DOI: 10.1016/j.ejca.2007.01.004] [Cited by in Crossref: 171] [Cited by in F6Publishing: 156] [Article Influence: 11.4] [Reference Citation Analysis]
87 Sawahara H, Shiraha H, Uchida D, Kato H, Kato R, Oyama A, Nagahara T, Iwamuro M, Horiguchi S, Tsutsumi K, Mandai M, Mimura T, Wada N, Takeuchi Y, Kuwaki K, Onishi H, Nakamura S, Watanabe M, Sakaguchi M, Takaki A, Nouso K, Yagi T, Nasu Y, Kumon H, Okada H. Promising therapeutic efficacy of a novel reduced expression in immortalized cells/dickkopf-3 expressing adenoviral vector for hepatocellular carcinoma: Novel Ad-REIC gene therapy for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2017;32:1769-77. [DOI: 10.1111/jgh.13757] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
88 Fako V, Yu Z, Henrich CJ, Ransom T, Budhu AS, Wang XW. Inhibition of wnt/β-catenin Signaling in Hepatocellular Carcinoma by an Antipsychotic Drug Pimozide. Int J Biol Sci 2016;12:768-75. [PMID: 27313491 DOI: 10.7150/ijbs.14718] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
89 Huang X, Gao Y, Qin J, Lu S. lncRNA MIAT promotes proliferation and invasion of HCC cells via sponging miR-214. American Journal of Physiology-Gastrointestinal and Liver Physiology 2018;314:G559-65. [DOI: 10.1152/ajpgi.00242.2017] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 10.5] [Reference Citation Analysis]
90 Sphyris N, Mani SA. pIgR: frenemy of inflammation, EMT, and HCC progression. J Natl Cancer Inst 2011;103:1644-5. [PMID: 22025623 DOI: 10.1093/jnci/djr421] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
91 Steiner K, Papadopoulou A, Yu D. The role of interventional radiology in the treatment of hepatocellular carcinoma. Semin Ultrasound CT MR 2013;34:89-101. [PMID: 23395321 DOI: 10.1053/j.sult.2012.11.008] [Reference Citation Analysis]
92 Ling D, Xia H, Park W, Hackett MJ, Song C, Na K, Hui KM, Hyeon T. pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma. ACS Nano 2014;8:8027-39. [PMID: 25093274 DOI: 10.1021/nn502074x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 11.4] [Reference Citation Analysis]
93 Zhao P, Malik S, Xing S. Epigenetic Mechanisms Involved in HCV-Induced Hepatocellular Carcinoma (HCC). Front Oncol 2021;11:677926. [PMID: 34336665 DOI: 10.3389/fonc.2021.677926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Xu M, Zhou L, Zhang P, Lu Y, Ge C, Yao W, Xing Y, Xiao W, Dong Y, Wu J, Cao R, Li T. Enhanced antitumor efficacy by combination treatment with a human umbilical vein endothelial cell vaccine and a tumor cell lysate-based vaccine. Tumor Biol 2013;34:3173-82. [DOI: 10.1007/s13277-013-0887-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
95 Mohan R, Sharma AK, Gupta S, Ramaa CS. Design, synthesis, and biological evaluation of novel 2,4-thiazolidinedione derivatives as histone deacetylase inhibitors targeting liver cancer cell line. Med Chem Res 2012;21:1156-65. [DOI: 10.1007/s00044-011-9623-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
96 Li GM, Liang CJ, Zhang DX, Zhang LJ, Wu JX, Xu YC. XB130 Knockdown Inhibits the Proliferation, Invasiveness, and Metastasis of Hepatocellular Carcinoma Cells and Sensitizes them to TRAIL-Induced Apoptosis. Chin Med J (Engl) 2018;131:2320-31. [PMID: 30246718 DOI: 10.4103/0366-6999.241800] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
97 Wei W, Chua MS, Grepper S, So S. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int J Cancer. 2010;126:2426-2436. [PMID: 19662654 DOI: 10.1002/ijc.24810] [Cited by in Crossref: 15] [Cited by in F6Publishing: 52] [Article Influence: 1.3] [Reference Citation Analysis]
98 Berasain C, Avila MA. The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis. J Gastroenterol. 2014;49:9-23. [PMID: 24318021 DOI: 10.1007/s00535-013-0907-x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 8.1] [Reference Citation Analysis]
99 Zhang R, Sun J, Zhang Y, Cheng S, Zhang X. Signal transduction disturbance related to hepatocarcinogenesis in mouse by prolonged exposure to Nanjing drinking water. Environ Sci Pollut Res 2013;20:6468-81. [DOI: 10.1007/s11356-013-1695-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
100 Liang C, Zhang J, Ge H, Xu Y, Ren S, Yue C, Li G, Wu J. Long non-coding RNA CASC2 in solid tumors: A meta-analysis. Clinica Chimica Acta 2018;486:357-68. [DOI: 10.1016/j.cca.2018.08.035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
101 Huang X, Li J, Zheng L, Zuo G, Han K, Li H, Liang P. Bioinformatics Analysis Reveals Potential Candidate Drugs for HCC. Pathol Oncol Res 2013;19:251-8. [DOI: 10.1007/s12253-012-9576-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
102 Wu BK, Chen QH, Pan D, Chang B, Sang LX. A novel therapeutic strategy for hepatocellular carcinoma: Immunomodulatory mechanisms of selenium and/or selenoproteins on a shift towards anti-cancer. Int Immunopharmacol 2021;96:107790. [PMID: 34162153 DOI: 10.1016/j.intimp.2021.107790] [Reference Citation Analysis]
103 Daskalow K, Pfander D, Weichert W, Rohwer N, Thelen A, Neuhaus P, Jonas S, Wiedenmann B, Benckert C, Cramer T. Distinct temporospatial expression patterns of glycolysis-related proteins in human hepatocellular carcinoma. Histochem Cell Biol. 2009;132:21-31. [PMID: 19350262 DOI: 10.1007/s00418-009-0590-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
104 Höpfner M, Schuppan D, Scherübl H. Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: Recent advances and future perspectives. World J Gastroenterol 2008; 14(16): 2461-2473 [PMID: 18442192 DOI: 10.3748/wjg.14.2461] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
105 Liu Y, Wang X, Sun CY, Wang J. Delivery of mitogen-activated protein kinase inhibitor for hepatocellular carcinoma stem cell therapy. ACS Appl Mater Interfaces 2015;7:1012-20. [PMID: 25522342 DOI: 10.1021/am508262j] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
106 Chen B, Xu X, Xiang M, Yang J, Yu T, Hu Y. Cytokine-induced killer cell combination with TACE in the treatment of hepatocellular cancers: a meta-analysis. Chin -Ger J Clin Oncol 2013;12:459-67. [DOI: 10.1007/s10330-013-1219-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
107 Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Ahn KS, Kumar AP, Sethi G. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1. J Cell Physiol 2012;227:2184-95. [PMID: 21792937 DOI: 10.1002/jcp.22954] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 10.8] [Reference Citation Analysis]
108 Yassin NYS, AbouZid SF, El-Kalaawy AM, Ali TM, Almehmadi MM, Ahmed OM. Silybum marianum total extract, silymarin and silibinin abate hepatocarcinogenesis and hepatocellular carcinoma growth via modulation of the HGF/c-Met, Wnt/β-catenin, and PI3K/Akt/mTOR signaling pathways. Biomed Pharmacother 2021;145:112409. [PMID: 34781148 DOI: 10.1016/j.biopha.2021.112409] [Reference Citation Analysis]
109 García-Irigoyen O, Latasa MU, Carotti S, Uriarte I, Elizalde M, Urtasun R, Vespasiani-Gentilucci U, Morini S, Benito P, Ladero JM, Rodriguez JA, Prieto J, Orbe J, Páramo JA, Fernández-Barrena MG, Berasain C, Avila MA. Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/C-X-C chemokine receptor 4 axis. Hepatology 2015;62:166-78. [PMID: 25808184 DOI: 10.1002/hep.27798] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
110 Bu P, Wan YJ. Fenretinide-induced apoptosis of Huh-7 hepatocellular carcinoma is retinoic acid receptor beta dependent. BMC Cancer 2007;7:236. [PMID: 18166136 DOI: 10.1186/1471-2407-7-236] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
111 Convertini P, Tramutola F, Iacobazzi V, Lupattelli P, Chiummiento L, Infantino V. Permethylated Anigopreissin A inhibits human hepatoma cell proliferation by mitochondria-induced apoptosis. Chemico-Biological Interactions 2015;237:1-8. [DOI: 10.1016/j.cbi.2015.05.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
112 Ceballos MP, Decándido G, Quiroga AD, Comanzo CG, Livore VI, Lorenzetti F, Lambertucci F, Chazarreta-Cifre L, Banchio C, Alvarez ML, Mottino AD, Carrillo MC. Inhibition of sirtuins 1 and 2 impairs cell survival and migration and modulates the expression of P-glycoprotein and MRP3 in hepatocellular carcinoma cell lines. Toxicol Lett 2018;289:63-74. [PMID: 29545174 DOI: 10.1016/j.toxlet.2018.03.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
113 Chie WC, Blazeby JM, Hsiao CF, Chiu HC, Poon RT, Mikoshiba N, Al-Kadhim G, Heaton N, Calara J, Collins P. Differences in health-related quality of life between European and Asian patients with hepatocellular carcinoma. Asia Pac J Clin Oncol. 2016; Epub ahead of print. [PMID: 27038366 DOI: 10.1111/ajco.12464] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
114 Swamy SG, Kameshwar VH, Shubha PB, Looi CY, Shanmugam MK, Arfuso F, Dharmarajan A, Sethi G, Shivananju NS, Bishayee A. Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma. Target Oncol 2017;12:1-10. [PMID: 27510230 DOI: 10.1007/s11523-016-0452-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 10.2] [Reference Citation Analysis]
115 Zhang A, Lakshmanan J, Motameni A, Harbrecht BG. MicroRNA-203 suppresses proliferation in liver cancer associated with PIK3CA, p38 MAPK, c-Jun, and GSK3 signaling. Mol Cell Biochem 2018;441:89-98. [PMID: 28887744 DOI: 10.1007/s11010-017-3176-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
116 Wei W, Chua MS, Grepper S, So SK. Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin. Mol Cancer. 2011;10:16. [PMID: 21314951 DOI: 10.1186/1476-4598-10-16] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 5.5] [Reference Citation Analysis]
117 An Q, Han C, Zhou Y, Li F, Li D, Zhang X, Yu Z, Duan Z, Kan Q. Matrine induces cell cycle arrest and apoptosis with recovery of the expression of miR-126 in the A549 non-small cell lung cancer cell line. Mol Med Rep 2016;14:4042-8. [PMID: 27665734 DOI: 10.3892/mmr.2016.5753] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
118 Elsonbaty SM, Zahran WE, Moawed FS. Gamma-irradiated β-glucan modulates signaling molecular targets of hepatocellular carcinoma in rats. Tumour Biol 2017;39:1010428317708703. [PMID: 28810822 DOI: 10.1177/1010428317708703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
119 Gao X, Han L, Ding N, Mu Y, Guan P, Hu C, Huang X. Bafilomycin C1 induces G0/G1 cell-cycle arrest and mitochondrial-mediated apoptosis in human hepatocellular cancer SMMC7721 cells. J Antibiot 2018;71:808-17. [DOI: 10.1038/s41429-018-0066-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
120 Tarocchi M, Polvani S, Marroncini G, Galli A. Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World J Gastroenterol 2014; 20(33): 11630-11640 [PMID: 25206269 DOI: 10.3748/wjg.v20.i33.11630] [Cited by in CrossRef: 101] [Cited by in F6Publishing: 87] [Article Influence: 12.6] [Reference Citation Analysis]
121 Wang Z, Yu B, Wang B, Yan J, Feng X, Wang Z, Wang L, Zhang H, Wu H, Wu J, Kong W, Yu X. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route. Oncotarget 2016;7:47287-301. [PMID: 27323824 DOI: 10.18632/oncotarget.10075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
122 Farcas M, Gavrea AA, Gulei D, Ionescu C, Irimie A, Catana CS, Berindan-Neagoe I. SIRT1 in the Development and Treatment of Hepatocellular Carcinoma. Front Nutr 2019;6:148. [PMID: 31608282 DOI: 10.3389/fnut.2019.00148] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
123 Kawashita M, Matsui N, Li Z, Miyazaki T. Preparation of porous yttrium oxide microparticles by gelation of ammonium alginate in aqueous solution containing yttrium ions. J Mater Sci: Mater Med 2010;21:1837-43. [DOI: 10.1007/s10856-010-4050-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
124 Pan Q, Pan K, Weng D, Zhao J, Zhang X, Wang D, Lv L, Jiang S, Zheng H, Xia J. Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma: ANXA3 IN HCC TUMORIGENESIS AND RESISTANCE. Mol Carcinog 2015;54:598-607. [DOI: 10.1002/mc.22126] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
125 Choi K, Joo H. Assessment of Gold Nanoparticles-Inhibited Cytochrome P450 3A4 Activity and Molecular Mechanisms Underlying Its Cellular Toxicity in Human Hepatocellular Carcinoma Cell Line C3A. Nanoscale Res Lett 2018;13:279. [PMID: 30203228 DOI: 10.1186/s11671-018-2684-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
126 Min J, Moon H, Yang HJ, Shin H, Hong SY, Kang S. Development of P22 Viral Capsid Nanocomposites as Anti-Cancer Drug, Bortezomib (BTZ), Delivery Nanoplatforms: Viral Capsid-Based Drug Delivery Nanoplatforms. Macromol Biosci 2014;14:557-64. [DOI: 10.1002/mabi.201300401] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
127 Zhang R, Cao Y, Bai L, Zhu C, Li R, He H, Liu Y, Wu K, Liu F, Wu J. The collagen triple helix repeat containing 1 facilitates hepatitis B virus-associated hepatocellular carcinoma progression by regulating multiple cellular factors and signal cascades. Mol Carcinog 2015;54:1554-66. [PMID: 25263696 DOI: 10.1002/mc.22229] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
128 Hoover AC, Strand GL, Nowicki PN, Anderson ME, Vermeer PD, Klingelhutz AJ, Bossler AD, Pottala JV, Hendriks WJ, Lee JH. Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway. Oncogene 2009;28:3960-70. [PMID: 19734941 DOI: 10.1038/onc.2009.251] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 3.8] [Reference Citation Analysis]
129 Abou-alfa GK, Jarnagin W, Lowery M, D'angelica M, Brown K, Ludwig E, Covey A, Kemeny N, Goodman KA, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2014. pp. 1373-1396.e8. [DOI: 10.1016/b978-1-4557-2865-7.00080-1] [Reference Citation Analysis]
130 Liu S, Gong J, Morishita A, Nomura T, Miyoshi H, Tani J, Kato K, Yoneyama H, Deguchi A, Mori H, Mimura S, Nomura K, Himoto T, Deguchi K, Okano K, Izuishi K, Suzuki Y, Kushida Y, Haba R, Iwama H, Masaki T. Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma. Exp Ther Med 2011;2:399-403. [PMID: 22977516 DOI: 10.3892/etm.2011.215] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
131 Latasa MU, Salis F, Urtasun R, Garcia-Irigoyen O, Elizalde M, Uriarte I, Santamaria M, Feo F, Pascale RM, Prieto J, Berasain C, Avila MA. Regulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system. PLoS One 2012;7:e52711. [PMID: 23285165 DOI: 10.1371/journal.pone.0052711] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
132 Scheele JS, Harder J, Stankovic Z, Räpple D, Dorn A, Spangenberg HC, Blum HE. Clinical response to Auron Misheil Therapy in a man with advanced multifocal hepatocellular carcinoma: A case report. J Med Case Rep 2011;5:478. [PMID: 21943068 DOI: 10.1186/1752-1947-5-478] [Reference Citation Analysis]
133 Liang C, Zhao T, Ge H, Xu Y, Ren S, Yue C, Li G, Wu J. The clinicopathological and prognostic value of Nanog in human gastrointestinal luminal cancer: A meta-analysis. International Journal of Surgery 2018;53:193-200. [DOI: 10.1016/j.ijsu.2018.03.050] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
134 Kaufmann R, Oettel C, Horn A, Halbhuber KJ, Eitner A, Krieg R, Katenkamp K, Henklein P, Westermann M, Böhmer FD, Ramachandran R, Saifeddine M, Hollenberg MD, Settmacher U. Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion. Carcinogenesis 2009;30:1487-96. [PMID: 19546160 DOI: 10.1093/carcin/bgp153] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
135 Reinacher-Schick A, Pohl M, Schmiegel W. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies. Nat Clin Pract Gastroenterol Hepatol 2008;5:250-67. [PMID: 18382435 DOI: 10.1038/ncpgasthep1097] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
136 Cui J, Shen HM, Lim LHK. The Role of Autophagy in Liver Cancer: Crosstalk in Signaling Pathways and Potential Therapeutic Targets. Pharmaceuticals (Basel) 2020;13:E432. [PMID: 33260729 DOI: 10.3390/ph13120432] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
137 Xie B, Wang DH, Spechler SJ. Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci. 2012;57:1122-1129. [PMID: 22451120 DOI: 10.1007/s10620-012-2136-1] [Cited by in Crossref: 79] [Cited by in F6Publishing: 81] [Article Influence: 7.9] [Reference Citation Analysis]
138 Gao X, Jiang Y, Han L, Chen X, Hu C, Su H, Mu Y, Guan P, Huang X. Effect of borrelidin on hepatocellular carcinoma cells in vitro and in vivo. RSC Adv 2017;7:44401-9. [DOI: 10.1039/c7ra08290h] [Cited by in Crossref: 7] [Article Influence: 1.4] [Reference Citation Analysis]
139 Rong XX, Wei F, Lin XL, Qin YJ, Chen L, Wang HY, Shen HF, Jia LT, Xie RY, Lin TY, Hao WC, Yang J, Yang S, Cheng YS, Huang WH, Li AM, Sun Y, Luo RC, Xiao D. Recognition and killing of cancer stem-like cell population in hepatocellular carcinoma cells by cytokine-induced killer cells via NKG2d-ligands recognition. Oncoimmunology. 2016;5:e1086060. [PMID: 27141341 DOI: 10.1080/2162402x.2015.1086060] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
140 Matthai SM, Ramakrishna B. Cancer stem cells in hepatocellular carcinoma--an immunohistochemical study with histopathological association. Indian J Med Res 2015;142:391-8. [PMID: 26609030 DOI: 10.4103/0971-5916.169195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
141 Richly H, Schultheis B, Adamietz IA, Kupsch P, Grubert M, Hilger RA, Ludwig M, Brendel E, Christensen O, Strumberg D. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer. 2009;45:579-587. [PMID: 19101137 DOI: 10.1016/j.ejca.2008.10.039] [Cited by in Crossref: 49] [Cited by in F6Publishing: 59] [Article Influence: 3.5] [Reference Citation Analysis]
142 Abdel aziz MT, El Asmar MF, Atta HM, Mahfouz S, Fouad HH, Roshdy NK, Rashed LA, Sabry D, Hassouna AA, Taha FM. Efficacy of mesenchymal stem cells in suppression of hepatocarcinorigenesis in rats: possible role of Wnt signaling. J Exp Clin Cancer Res 2011;30:49. [PMID: 21545718 DOI: 10.1186/1756-9966-30-49] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
143 Furuse J. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Biologics 2008;2:779-88. [PMID: 19707458 DOI: 10.2147/btt.s3410] [Cited by in Crossref: 3] [Cited by in F6Publishing: 22] [Article Influence: 0.3] [Reference Citation Analysis]
144 Kim YI, Ahn BC, Ronald JA, Katzenberg R, Singh A, Paulmurugan R, Ray S, Gambhir SS, Hofmann LV. Intratumoral versus intravenous gene therapy using a transcriptionally targeted viral vector in an orthotopic hepatocellular carcinoma rat model. J Vasc Interv Radiol 2012;23:704-11. [PMID: 22387029 DOI: 10.1016/j.jvir.2012.01.053] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
145 Faraj Shaglouf LH, Ranjpour M, Wajid S, Jain SK. Elevated expression of cellular SYNE1, MMP10, and GTPase1 and their regulatory role in hepatocellular carcinoma progression. Protoplasma 2020;257:157-67. [PMID: 31428857 DOI: 10.1007/s00709-019-01423-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
146 Kawashita M, Matsui N, Li Z, Miyazaki T, Kanetaka H. Preparation, structure, and in vitro chemical durability of yttrium phosphate microspheres for intra-arterial radiotherapy. J Biomed Mater Res 2011;99B:45-50. [DOI: 10.1002/jbm.b.31870] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
147 Lim S, Kim H, Jung G. p53 inhibits tumor cell invasion via the degradation of snail protein in hepatocellular carcinoma. FEBS Letters 2010;584:2231-6. [DOI: 10.1016/j.febslet.2010.04.006] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 5.8] [Reference Citation Analysis]
148 Wu J, Omar HA, Lee Y, Teng Y, Chen P, Chen Y, Huang H, Lee K, Hung J. 6-Shogaol induces cell cycle arrest and apoptosis in human hepatoma cells through pleiotropic mechanisms. European Journal of Pharmacology 2015;762:449-58. [DOI: 10.1016/j.ejphar.2015.06.032] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
149 Thapa RK, Choi JY, Poudel BK, Hiep TT, Pathak S, Gupta B, Choi HG, Yong CS, Kim JO. Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2015;7:20360-8. [PMID: 26315487 DOI: 10.1021/acsami.5b06203] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 8.0] [Reference Citation Analysis]
150 Chen J, Zhu S, Tong L, Li J, Chen F, Han Y, Zhao M, Xiong W. Superparamagnetic iron oxide nanoparticles mediated (131)I-hVEGF siRNA inhibits hepatocellular carcinoma tumor growth in nude mice. BMC Cancer. 2014;14:114. [PMID: 24555445 DOI: 10.1186/1471-2407-14-114] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
151 Tsai MC, Chen KD, Wang CC, Huang KT, Wu CH, Kuo IY, Chen LY, Hu TH, Goto S, Nakano T, Dorling A, McVey JH, Chen CL, Lin CC. Factor VII promotes hepatocellular carcinoma progression through ERK-TSC signaling. Cell Death Discov 2015;1:15051. [PMID: 27551480 DOI: 10.1038/cddiscovery.2015.51] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
152 Lee J, Lee H, Yun S, Jung KH, Jeong Y, Yan HH, Hong S, Hong S. IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma. Cancer Letters 2013;329:99-108. [DOI: 10.1016/j.canlet.2012.10.028] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
153 Berasain C, Avila MA. Regulation of hepatocyte identity and quiescence. Cell Mol Life Sci 2015;72:3831-51. [DOI: 10.1007/s00018-015-1970-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
154 Liang C, Xu Y, Ge H, Li G, Wu J. The clinicopathological and prognostic value of HSP27 in hepatocellular carcinoma: a systematic review and meta-analysis. Onco Targets Ther 2018;11:1293-303. [PMID: 29563808 DOI: 10.2147/OTT.S154227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
155 Chie W, Blazeby JM, Hsiao C, Chiu H, Poon RT, Mikoshiba N, Al-kadhimi G, Heaton N, Calara J, Collins P, Caddick K, Costantini A, Vilgrain V, Trinquart L, Chiang C; On behalf of the EORTC Quality of Life Group. International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life ques. Hepatology 2012;55:1122-9. [DOI: 10.1002/hep.24798] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
156 Xie Z, Choong PF, Poon LF, Zhou J, Khng J, Jasinghe VJ, Palaniyandi S, Chen CS. Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion. Cancer Chemother Pharmacol 2008;62:949-57. [PMID: 18259754 DOI: 10.1007/s00280-008-0684-z] [Cited by in F6Publishing: 32] [Reference Citation Analysis]
157 Sangro B, Mazzolini G, Ruiz M, Ruiz J, Quiroga J, Herrero I, Qian C, Benito A, Larrache J, Olagüe C, Boan J, Peñuelas I, Sádaba B, Prieto J. A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Ther 2010;17:837-43. [DOI: 10.1038/cgt.2010.40] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 6.2] [Reference Citation Analysis]
158 Berasain C, Castillo J, Perugorría M, Prieto J, Avila M. Amphiregulin: A new growth factor in hepatocarcinogenesis. Cancer Letters 2007;254:30-41. [DOI: 10.1016/j.canlet.2007.01.015] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 3.9] [Reference Citation Analysis]
159 Zhao M, Wang Y, Liu Y, Zhang W, Liu Y, Yang X, Cao Y, Wang S. C7 peptide inhibits hepatocellular carcinoma metastasis by targeting the HGF/c-Met signaling pathway. Cancer Biol Ther 2019;20:1430-42. [PMID: 31441380 DOI: 10.1080/15384047.2019.1647051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
160 He M, Yu L, Yang Y, Zou B, Ma W, Yu M, Lu J, Xiong G, Yu Z, Li A. Delivery of triptolide with reduction-sensitive polymer nanoparticles for liver cancer therapy on patient-derived xenografts models. Chinese Chemical Letters 2020;31:3178-82. [DOI: 10.1016/j.cclet.2020.05.034] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
161 Choi SH, Park BK, Lee KW, Chang J, Lee Y, Kwon HJ. Effect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell-lines. BMB Rep 2015;48:565-70. [PMID: 25739391 DOI: 10.5483/bmbrep.2015.48.10.268] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
162 Long Z, Wang B, Tao D, Liu Y, Zhang J, Tan J, Luo J, Shi F, Tao Z. Clinical research on alternating hyperfraction radiotherapy for massive hepatocellular carcinoma. Oncol Lett 2015;10:523-7. [PMID: 26171062 DOI: 10.3892/ol.2015.3185] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
163 Fan X, Zhao Z, Song J, Zhang D, Wu F, Tu J, Xu M, Ji J. LncRNA-SNHG6 promotes the progression of hepatocellular carcinoma by targeting miR-6509-5p and HIF1A. Cancer Cell Int 2021;21:150. [PMID: 33663502 DOI: 10.1186/s12935-021-01835-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA. Inflammation and liver cancer: new molecular links . Ann N Y Acad Sci. 2009;1155:206-221. [PMID: 19250206 DOI: 10.1111/j.1749-6632.2009.03704.x] [Cited by in Crossref: 266] [Cited by in F6Publishing: 250] [Article Influence: 20.5] [Reference Citation Analysis]
165 Kalva SP, Thabet A, Wicky S. Recent advances in transarterial therapy of primary and secondary liver malignancies. Radiographics. 2008;28:101-117. [PMID: 18203933 DOI: 10.1148/rg.281075115] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
166 Huang W, Gao F, Li K, Wang W, Lai YR, Tang SH, Yang DH. Decaprenyl diphosphate synthase subunit 2 as a prognosis factor in hepatocellular carcinoma. World J Gastroenterol 2015; 21(10): 3055-3065 [PMID: 25780306 DOI: 10.3748/wjg.v21.i10.3055] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
167 Chen SY, Lee YR, Hsieh MC, Omar HA, Teng YN, Lin CY, Hung JH. Enhancing the Anticancer Activity of Antrodia cinnamomea in Hepatocellular Carcinoma Cells via Cocultivation With Ginger: The Impact on Cancer Cell Survival Pathways. Front Pharmacol 2018;9:780. [PMID: 30072899 DOI: 10.3389/fphar.2018.00780] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
168 Varshosaz J, Jafarian A, Salehi G, Zolfaghari B. Comparing different sterol containing solid lipid nanoparticles for targeted delivery of quercetin in hepatocellular carcinoma. J Liposome Res. 2014;24:191-203. [PMID: 24354715 DOI: 10.3109/08982104.2013.868476] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
169 Shin JW, Chung YH. Molecular targeted therapy for hepatocellular carcinoma: Current and future. World J Gastroenterol 2013; 19(37): 6144-6155 [PMID: 24115810 DOI: 10.3748/wjg.v19.i37.6144] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 55] [Article Influence: 5.6] [Reference Citation Analysis]
170 Jue C, Min Z, Zhisheng Z, Lin C, Yayun Q, Xuanyi W, Feng J, Haibo W, Youyang S, Tadashi H, Shintaro I, Shiyu G, Yanqing L. COE inhibits vasculogenic mimicry in hepatocellular carcinoma via suppressing Notch1 signaling. J Ethnopharmacol 2017;208:165-73. [PMID: 28694103 DOI: 10.1016/j.jep.2017.07.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
171 Abou-alfa GK, Jarnagin W, El Dika I, D'angelica M, Lowery M, Brown K, Ludwig E, Kemeny N, Covey A, Crane CH, Harding J, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 1314-1341.e11. [DOI: 10.1016/b978-0-323-47674-4.00077-3] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
172 Campbell JS, Johnson MM, Bauer RL, Hudkins KL, Gilbertson DG, Riehle KJ, Yeh MM, Alpers CE, Fausto N. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis. Differentiation. 2007;75:843-852. [PMID: 17999742 DOI: 10.1111/j.1432-0436.2007.00235.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
173 Zha L, Fan L, Sun G, Wang H, Ma T, Zhong F, Wei W. Melatonin sensitizes human hepatoma cells to endoplasmic reticulum stress-induced apoptosis. J Pineal Res. 2012;52:322-331. [PMID: 22225575 DOI: 10.1111/j.1600-079x.2011.00946.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
174 Hesketh RL, Zhu AX, Oklu R. Hepatocellular carcinoma: can circulating tumor cells and radiogenomics deliver personalized care? Am J Clin Oncol 2015;38:431-6. [PMID: 25238287 DOI: 10.1097/COC.0000000000000123] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
175 Rahman M, Almalki WH, Alrobaian M, Iqbal J, Alghamdi S, Alharbi KS, Alruwaili NK, Hafeez A, Shaharyar A, Singh T, Waris M, Kumar V, Beg S. Nanocarriers-loaded with natural actives as newer therapeutic interventions for treatment of hepatocellular carcinoma. Expert Opin Drug Deliv 2021;18:489-513. [PMID: 33225771 DOI: 10.1080/17425247.2021.1854223] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
176 Kim YJ, Jeon Y, Kim T, Lim WC, Ham J, Park YN, Kim TJ, Ko H. Combined treatment with zingerone and its novel derivative synergistically inhibits TGF-β1 induced epithelial-mesenchymal transition, migration and invasion of human hepatocellular carcinoma cells. Bioorg Med Chem Lett 2017;27:1081-8. [PMID: 28110870 DOI: 10.1016/j.bmcl.2016.12.042] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
177 Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK, Goldstein RM. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent). 2008;21:266-280. [PMID: 18628926 DOI: 10.1080/08998280.2008.11928410] [Cited by in Crossref: 105] [Cited by in F6Publishing: 102] [Article Influence: 9.5] [Reference Citation Analysis]
178 Abdel-hamid NM, Abouzied MM, Nazmy MH, Fawzy MA, Gerges AS. A suggested guiding panel of seromarkers for efficient discrimination between primary and secondary human hepatocarcinoma. Tumor Biol 2016;37:2539-46. [DOI: 10.1007/s13277-015-4025-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
179 Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010;29:4989-5005. [PMID: 20639898 DOI: 10.1038/onc.2010.236] [Cited by in Crossref: 562] [Cited by in F6Publishing: 546] [Article Influence: 46.8] [Reference Citation Analysis]
180 Spangenberg HC, Thimme R, Blum HE. Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009;6:423-32. [DOI: 10.1038/nrgastro.2009.86] [Cited by in Crossref: 80] [Cited by in F6Publishing: 81] [Article Influence: 6.2] [Reference Citation Analysis]
181 Jayachandran A, Dhungel B, Steel JC. Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. J Hematol Oncol. 2016;9:74. [PMID: 27578206 DOI: 10.1186/s13045-016-0307-9] [Cited by in Crossref: 88] [Cited by in F6Publishing: 93] [Article Influence: 14.7] [Reference Citation Analysis]
182 Enguita-Germán M, Fortes P. Targeting the insulin-like growth factor pathway in hepatocellular carcinoma. World J Hepatol 2014; 6(10): 716-737 [PMID: 25349643 DOI: 10.4254/wjh.v6.i10.716] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
183 Wörns MA, Galle PR. Novel inhibitors in development for hepatocellular carcinoma. Expert Opin Investig Drugs 2010;19:615-29. [PMID: 20374038 DOI: 10.1517/13543781003767418] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
184 Hosseini-Khah Z, Babaei MR, Tehrani M, Cucchiarini M, Madry H, Ajami A, Rakhshani N, Rafiei A, Nikbin B. SOX2 and Bcl-2 as a Novel Prognostic Value in Hepatocellular Carcinoma Progression. Curr Oncol 2021;28:3015-29. [PMID: 34436030 DOI: 10.3390/curroncol28040264] [Reference Citation Analysis]
185 Shahin YR, Elguindy NM, Abdel Bary A, Balbaa M. The protective mechanism of Nigella sativa against diethylnitrosamine-induced hepatocellular carcinoma through its antioxidant effect and EGFR/ERK1/2 signaling. Environ Toxicol 2018. [PMID: 29923357 DOI: 10.1002/tox.22574] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
186 Beurel E, Blivet-Van Eggelpoël MJ, Kornprobst M, Moritz S, Delelo R, Paye F, Housset C, Desbois-Mouthon C. Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells. Biochem Pharmacol. 2009;77:54-65. [PMID: 18938143 DOI: 10.1016/j.bcp.2008.09.026] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
187 Mayoral R, Mollá B, Flores JM, Boscá L, Casado M, Martín-Sanz P. Constitutive expression of cyclo-oxygenase 2 transgene in hepatocytes protects against liver injury. Biochem J 2008;416:337-46. [PMID: 18671671 DOI: 10.1042/BJ20081224] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
188 Galle PR. Sorafenib in advanced hepatocellular carcinoma - We have won a battle not the war. J Hepatol. 2008;49:871-873. [PMID: 18817997 DOI: 10.1016/j.jhep.2008.09.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
189 Teng CF, Wu HC, Shyu WC, Jeng LB, Su IJ. Pre-S2 Mutant-Induced Mammalian Target of Rapamycin Signal Pathways as Potential Therapeutic Targets for Hepatitis B Virus-Associated Hepatocellular Carcinoma. Cell Transplant 2017;26:429-38. [PMID: 28195035 DOI: 10.3727/096368916X694382] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
190 Lencioni R. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. Crit Rev Oncol Hematol. 2012;83:216-224. [PMID: 22142656 DOI: 10.1016/j.critrevonc.2011.10.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
191 Xie Y, Huang L, Chen L, Lin X, Chen L, Zheng Q. Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment. World J Surg Oncol 2017;15:209. [PMID: 29179719 DOI: 10.1186/s12957-017-1278-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
192 Imamoto R, Okano JI, Sawada S, Fujise Y, Abe R, Murawaki Y. Null anticarcinogenic effect of silymarin on diethylnitrosamine-induced hepatocarcinogenesis in rats. Exp Ther Med 2014;7:31-8. [PMID: 24348760 DOI: 10.3892/etm.2013.1391] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
193 Calcagnì A, Kors L, Verschuren E, De Cegli R, Zampelli N, Nusco E, Confalonieri S, Bertalot G, Pece S, Settembre C, Malouf GG, Leemans JC, de Heer E, Salvatore M, Peters DJ, Di Fiore PP, Ballabio A. Modelling TFE renal cell carcinoma in mice reveals a critical role of WNT signaling. Elife 2016;5:e17047. [PMID: 27668431 DOI: 10.7554/eLife.17047] [Cited by in Crossref: 40] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
194 Liang X, Wu B, Shang H, Han X, Jing H, Sun Y, Cheng W. VTIQ evaluates antitumor effects of NET-1 siRNA by UTMD in HCC xenograft models. Oncol Lett 2018;16:2893-902. [PMID: 30127877 DOI: 10.3892/ol.2018.8994] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
195 Ren F, Wu H, Lei Y, Zhang H, Liu R, Zhao Y, Chen X, Zeng D, Tong A, Chen L, Wei Y, Huang C. Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. Mol Cancer 2010;9:81. [PMID: 20403181 DOI: 10.1186/1476-4598-9-81] [Cited by in Crossref: 83] [Cited by in F6Publishing: 83] [Article Influence: 6.9] [Reference Citation Analysis]
196 Liang C, Liu J, Ge H, Xu Y, Li G, Wu J. The clinicopathological and prognostic value of long non-coding RNA ZEB1-AS1 in solid tumors: A meta-analysis. Clinica Chimica Acta 2018;484:91-8. [DOI: 10.1016/j.cca.2018.05.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
197 Feo F, Frau M, Pascale RM. Interaction of major genes predisposing to hepatocellular carcinoma with genes encoding signal transduction pathways influences tumor phenotype and prognosis. World J Gastroenterol 2008; 14(43): 6601-6615 [PMID: 19034960 DOI: 10.3748/wjg.14.6601] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
198 Wang J, Feng L, Zhang L. Combining cellular immunotherapy was an optional choice for unresectable advanced HCC: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2021;45:101440. [PMID: 32709504 DOI: 10.1016/j.clinre.2020.04.010] [Reference Citation Analysis]
199 Laloo B, Maurel M, Jalvy-delvaille S, Sagliocco F, Grosset C. Analysis of post-transcriptional regulation using the FunREG method. Biochemical Society Transactions 2010;38:1608-14. [DOI: 10.1042/bst0381608] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
200 Zhang Y, Andrews GK, Wang L. Zinc-induced Dnmt1 expression involves antagonism between MTF-1 and nuclear receptor SHP. Nucleic Acids Res 2012;40:4850-60. [PMID: 22362755 DOI: 10.1093/nar/gks159] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
201 Martín-Renedo J, Mauriz JL, Jorquera F, Ruiz-Andrés O, González P, González-Gallego J. Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J Pineal Res. 2008;45:532-540. [PMID: 19012662 DOI: 10.1111/j.1600-079x.2008.00641.x] [Cited by in Crossref: 145] [Cited by in F6Publishing: 56] [Article Influence: 10.4] [Reference Citation Analysis]
202 Kang J, Oishi J, Kim J, Ijuin M, Toita R, Jun B, Asai D, Mori T, Niidome T, Tanizawa K, Kuroda S, Katayama Y. Hepatoma-targeted gene delivery using a tumor cell–specific gene regulation system combined with a human liver cell–specific bionanocapsule. Nanomedicine: Nanotechnology, Biology and Medicine 2010;6:583-9. [DOI: 10.1016/j.nano.2010.01.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
203 Lin ZZ, Hsu HC, Hsu CH, Yeh PY, Huang CY, Huang YF, Chen TJ, Kuo SH, Hsu C, Hu FC, Jeng YM, Chung Y, Cheng AL. The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. J Hepatol 2009;50:518-27. [PMID: 19155085 DOI: 10.1016/j.jhep.2008.10.022] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
204 Liang C, Qi Z, Ge H, Liang C, Zhang Y, Wang Z, Li R, Guo J. Long non-coding RNA PCAT-1 in human cancers: A meta-analysis. Clinica Chimica Acta 2018;480:47-55. [DOI: 10.1016/j.cca.2018.01.043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
205 Ma B, Jiang H, Jia J, Di L, Song G, Yu J, Zhu Y, Lu Z, Wang X, Zhou X, Ren J. Murine bone marrow stromal cells pulsed with homologous tumor-derived exosomes inhibit proliferation of liver cancer cells. Clin Transl Oncol 2012;14:764-73. [PMID: 22855153 DOI: 10.1007/s12094-012-0860-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
206 Limeres MJ, Moretton MA, Bernabeu E, Chiappetta DA, Cuestas ML. Thinking small, doing big: Current success and future trends in drug delivery systems for improving cancer therapy with special focus on liver cancer. Materials Science and Engineering: C 2019;95:328-41. [DOI: 10.1016/j.msec.2018.11.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
207 Wu L, Pang Y, Qin G, Xi G, Wu S, Wang X, Chen T. Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives. PLoS One 2017;12:e0171840. [PMID: 28182780 DOI: 10.1371/journal.pone.0171840] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
208 Lo CH, Chang CM, Tang SW, Pan WY, Fang CC, Chen Y, Wu PY, Chen KY, Ma HI, Xiao X, Tao MH. Differential antitumor effect of interleukin-12 family cytokines on orthotopic hepatocellular carcinoma. J Gene Med 2010;12:423-34. [PMID: 20440753 DOI: 10.1002/jgm.1452] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
209 Li X, Dai D, Song X, Liu J, Zhu L, Xu W. A meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2014;38:583-591. [PMID: 24924902 DOI: 10.1016/j.clinre.2014.04.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
210 Hari Babu L, Perumal S, Balasubramanian MP. Myrtenal attenuates diethylnitrosamine-induced hepatocellular carcinoma in rats by stabilizing intrinsic antioxidants and modulating apoptotic and anti-apoptotic cascades. Cell Oncol 2012;35:269-83. [DOI: 10.1007/s13402-012-0086-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
211 Szepeshazi K, Schally AV, Treszl A, Seitz S, Halmos G. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin. Anti-Cancer Drugs 2008;19:349-58. [DOI: 10.1097/cad.0b013e3282f9adce] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
212 Li RW, Kirkland NT, Truong J, Wang J, Smith PN, Birbilis N, Nisbet DR. The influence of biodegradable magnesium alloys on the osteogenic differentiation of human mesenchymal stem cells. J Biomed Mater Res A 2014;102:4346-57. [PMID: 24677428 DOI: 10.1002/jbm.a.35111] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
213 Nagai H, Mukozu T, Matsui D, Kanekawa T, Kanayama M, Wakui N, Momiyama K, Shinohara M, Iida K, Ishii K, Igarashi Y, Sumino Y. Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma. Clin Dev Immunol 2012;2012:607851. [PMID: 22666283 DOI: 10.1155/2012/607851] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
214 Hosseini FS, Falahati-Pour SK, Hajizadeh MR, Khoshdel A, Mirzaei MR, Ahmadirad H, Behroozi R, Jafari N, Mahmoodi M. Persian shallot, Allium hirtifolium Boiss, induced apoptosis in human hepatocellular carcinoma cells. Cytotechnology 2017;69:551-63. [PMID: 28397098 DOI: 10.1007/s10616-017-0093-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
215 Hernandez-Alcoceba R, Sangro B, Berraondo P, Gonzalez-Aseguinolaza G, Prieto J. Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives. Expert Opin Investig Drugs 2013;22:827-41. [PMID: 23594171 DOI: 10.1517/13543784.2013.793307] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
216 Zhou C, Liu J, Li Y, Liu L, Zhang X, Ma CY, Hua SC, Yang M, Yuan Q. microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma. FEBS Lett. 2011;585:1828-1834. [PMID: 21530512 DOI: 10.1016/j.febslet.2011.04.040] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 4.0] [Reference Citation Analysis]
217 Hua H, Wang J, Zhong P, Mou T, Liu P, Xie F. The clinical prognostic value of lncRNA LINC00675 in cancer patients: A meta-analysis. Medicine (Baltimore) 2021;100:e25244. [PMID: 33879657 DOI: 10.1097/MD.0000000000025244] [Reference Citation Analysis]
218 Guo Y, Zhang Y, Li J, Zhang Y, Lu Y, Jiang X, He X, Ma H, An S, Jiang C. Cell microenvironment-controlled antitumor drug releasing-nanomicelles for GLUT1-targeting hepatocellular carcinoma therapy. ACS Appl Mater Interfaces 2015;7:5444-53. [PMID: 25686400 DOI: 10.1021/am5091462] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 5.9] [Reference Citation Analysis]
219 Nie JJ, Liu Y, Qi Y, Zhang N, Yu B, Chen DF, Yang M, Xu FJ. Charge-reversal nanocomolexes-based CRISPR/Cas9 delivery system for loss-of-function oncogene editing in hepatocellular carcinoma. J Control Release 2021;333:362-73. [PMID: 33785418 DOI: 10.1016/j.jconrel.2021.03.030] [Reference Citation Analysis]
220 Liu Z, Chen D, Ning F, Du J, Wang H. EGF is highly expressed in hepatocellular carcinoma (HCC) and promotes motility of HCC cells via fibronectin. J Cell Biochem 2018;119:4170-83. [DOI: 10.1002/jcb.26625] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
221 Santambrogio R, Opocher E, Zuin M, Selmi C, Bertolini E, Costa M, Conti M, Montorsi M. Surgical resection versus laparoscopic radiofrequency ablation in patients with hepatocellular carcinoma and Child-Pugh class a liver cirrhosis. Ann Surg Oncol. 2009;16:3289-3298. [PMID: 19727960 DOI: 10.1245/s10434-009-0678-z] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
222 Datta J, Majumder S, Kutay H, Motiwala T, Frankel W, Costa R, Cha HC, MacDougald OA, Jacob ST, Ghoshal K. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res 2007;67:2736-46. [PMID: 17363595 DOI: 10.1158/0008-5472.CAN-06-4433] [Cited by in Crossref: 82] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
223 Ramezani M, Ramezani M, Hassanshahi G, Mahmoodi M, Zainodini N, Darekordi A, Khanamani Falahati-pour S, Mirzaei MR. Does the Novel Class of (2R, 4S)-N-(2, 5-Difluorophenyl)-4-Hydroxy-1-(2, 2, 2-Trifluoroacetyl) Pyrrolidine-2-Carboxamide’s Have Any Effect on Cell Viability and Apoptosis of Human Hepatocellular Carcinoma Cells? Int J Cancer Manag 2017;10. [DOI: 10.5812/ijcm.8413] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
224 Ma SH, Chen GG, Yip J, Lai PB. Therapeutic effect of alpha-fetoprotein promoter-mediated tBid and chemotherapeutic agents on orthotopic liver tumor in mice. Gene Ther. 2010;17:905-912. [PMID: 20336154 DOI: 10.1038/gt.2010.34] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
225 Chao DC, Lin LJ, Kao ST, Huang HC, Chang CS, Liang JA, Wu SL, Hsiang CY, Ho TY. Inhibitory effects of Zuo-Jin-Wan and its alkaloidal ingredients on activator protein 1, nuclear factor-κB, and cellular transformation in HepG2 cells. Fitoterapia 2011;82:696-703. [PMID: 21356280 DOI: 10.1016/j.fitote.2011.02.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
226 Barajas M, Franchi F, Clavel C, Aranguren XL, Kramer MG, Abizanda G, Merino J, Moreno C, Gárate L, Guitart A, Narvaiza I, Gutiérrez-Perez M, Riezu-Boj JI, Berasain C, Prieto J, Prósper F. Multipotent Adult Progenitor Cells (MAPC) contribute to hepatocarcinoma neovasculature. Biochem Biophys Res Commun 2007;364:92-9. [PMID: 17931602 DOI: 10.1016/j.bbrc.2007.09.106] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
227 Meguro M, Mizuguchi T, Kawamoto M, Hirata K. The molecular pathogenesis and clinical implications of hepatocellular carcinoma. Int J Hepatol 2011;2011:818672. [PMID: 22187659 DOI: 10.4061/2011/818672] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
228 Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 2008;395:19-26. [PMID: 18538135 DOI: 10.1016/j.cca.2008.05.010] [Cited by in Crossref: 136] [Cited by in F6Publishing: 126] [Article Influence: 9.7] [Reference Citation Analysis]
229 Cai J, Tong Y, Huang L, Xia L, Guo H, Wu H, Kong X, Xia Q. Identification and validation of a potent multi-mRNA signature for the prediction of early relapse in hepatocellular carcinoma. Carcinogenesis 2019;40:840-52. [DOI: 10.1093/carcin/bgz018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
230 He N, Park K, Zhang Y, Huang J, Lu S, Wang L. Epigenetic Inhibition of Nuclear Receptor Small Heterodimer Partner Is Associated With and Regulates Hepatocellular Carcinoma Growth. Gastroenterology 2008;134:793-802. [DOI: 10.1053/j.gastro.2008.01.006] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 5.1] [Reference Citation Analysis]
231 Wang L, Xie Y, Fang H, Zhang X, Pan H, Yan S. Long noncoding RNA DANCR in various cancers: a meta-analysis and bioinformatics. Cancer Manag Res 2019;11:6581-92. [PMID: 31410056 DOI: 10.2147/CMAR.S200922] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
232 Frau M, Biasi F, Feo F, Pascale RM. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Mol Aspects Med 2010;31:179-93. [PMID: 20176048 DOI: 10.1016/j.mam.2010.02.007] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 4.7] [Reference Citation Analysis]
233 Zhang M, Zhang H, Sun C, Shan X, Yang X, Li-Ling J, Deng Y. Targeted constitutive activation of signal transducer and activator of transcription 3 in human hepatocellular carcinoma cells by cucurbitacin B. Cancer Chemother Pharmacol. 2009;63:635-642. [PMID: 18521604 DOI: 10.1007/s00280-008-0780-0] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
234 Yang L, Cao J, Wei J, Deng J, Hou X, Hao E, Du Z, Zou L, Li P. Antiproliferative activity of berberine in HepG2 cells via inducing apoptosis and arresting cell cycle. Food Funct 2021;12:12115-26. [PMID: 34787617 DOI: 10.1039/d1fo02783b] [Reference Citation Analysis]
235 Liang C, Xu Y, Ge H, Li G, Wu J. Clinicopathological and prognostic significance of OCT4 in patients with hepatocellular carcinoma: a meta-analysis. Onco Targets Ther 2018;11:47-57. [PMID: 29317833 DOI: 10.2147/OTT.S151390] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
236 Qi MH. Signal pathways associated with epithelial-mesenchymal transition in metastasis of primary hepatocelluar carcinoma. Shijie Huaren Xiaohua Zazhi 2012; 20(11): 953-958 [DOI: 10.11569/wcjd.v20.i11.953] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
237 Chen T, Yang P, Jia Y. Molecular mechanisms of astragaloside‑IV in cancer therapy (Review). Int J Mol Med 2021;47:13. [PMID: 33448320 DOI: 10.3892/ijmm.2021.4846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
238 Li Z, Yao Z, Zhang Y, Yao J, Pan Z, Chen J. Polyethylenimine (PEI)-Mediated E1A Increases the Sensitivity of Hepatocellular Carcinoma Cells to Chemotherapy. Med Sci Monit Basic Res 2019;25:113-20. [PMID: 30956277 DOI: 10.12659/MSMBR.914811] [Reference Citation Analysis]
239 Chan KT, Meng FY, Li Q, Ho CY, Lam TS, To Y, Lee WH, Li M, Chu KH, Toh M. Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration. Cancer Lett. 2010;294:118-124. [PMID: 20153103 DOI: 10.1016/j.canlet.2010.01.029] [Cited by in Crossref: 154] [Cited by in F6Publishing: 138] [Article Influence: 12.8] [Reference Citation Analysis]
240 Ceballos MP, Rigalli JP, Ceré LI, Semeniuk M, Catania VA, Ruiz ML. ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma. Curr Med Chem 2019;26:1224-50. [PMID: 29303075 DOI: 10.2174/0929867325666180105103637] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
241 Zhang L, Guo Y, Li B, Qu J, Zang C, Li F, Wang Y, Pang H, Li S, Liu Q. Identification of biomarkers for hepatocellular carcinoma using network-based bioinformatics methods. Eur J Med Res 2013;18:35. [PMID: 24083576 DOI: 10.1186/2047-783X-18-35] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
242 Kumari R, Sharma A, Ajay AK, Bhat MK. Mitomycin C induces bystander killing in homogeneous and heterogeneous hepatoma cellular models. Mol Cancer 2009;8:87. [PMID: 19845939 DOI: 10.1186/1476-4598-8-87] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
243 Liang C, Zhao J, Ge H, Li G, Wu J. Clinicopathological and prognostic significance of FoxM1 in hepatocellular carcinoma patients: a meta-analysis. Onco Targets Ther 2018;11:3561-71. [PMID: 29950861 DOI: 10.2147/OTT.S155541] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
244 Shen YC, Hsu C, Cheng AL. Molecular targeted therapy for advanced hepatocellular carcinoma. Targ Oncol 2007;2:199-210. [DOI: 10.1007/s11523-007-0058-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
245 Huynh H, Chow KH, Soo KC, Toh HC, Choo SP, Foo KF, Poon D, Ngo VC, Tran E. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med. 2009;13:1371-1380. [PMID: 18466352 DOI: 10.1111/j.1582-4934.2008.00364.x] [Cited by in Crossref: 95] [Cited by in F6Publishing: 99] [Article Influence: 6.8] [Reference Citation Analysis]
246 Che Y, Ye F, Xu R, Qing H, Wang X, Yin F, Cui M, Burstein D, Jiang B, Zhang DY. Co-expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma. Am J Pathol 2012;180:1798-807. [PMID: 22429965 DOI: 10.1016/j.ajpath.2012.01.016] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
247 Shen J, Chen J, Ma J, Fan L, Zhang X, Yue T, Yan Y, Zhang Y. Enhanced lysosome escape mediated by 1,2-dicarboxylic-cyclohexene anhydride-modified poly-l-lysine dendrimer as a gene delivery system. Asian J Pharm Sci 2020;15:759-76. [PMID: 33363631 DOI: 10.1016/j.ajps.2019.12.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
248 Cheng L, Liu M, Wang C, Liu H, Zhang Y, Lin X. CI431, an Aqueous Compound from Ciona intestinalis L., Induces Apoptosis through a Mitochondria-Mediated Pathway in Human Hepatocellular Carcinoma Cells. Evid Based Complement Alternat Med 2011;2011:292873. [PMID: 21860650 DOI: 10.1155/2011/292873] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
249 Wang Z, Wei W, Sun CK, Chua MS, So S. Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth. Liver Int 2015;35:1403-15. [PMID: 25098386 DOI: 10.1111/liv.12651] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
250 Berasain C, Perugorria MJ, Latasa MU, Castillo J, Goñi S, Santamaría M, Prieto J, Avila MA. The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood) 2009;234:713-25. [PMID: 19429859 DOI: 10.3181/0901-MR-12] [Cited by in Crossref: 88] [Cited by in F6Publishing: 47] [Article Influence: 6.8] [Reference Citation Analysis]
251 Gao S, Hu W, Huang X, Huang X, Chen W, Hao L, Chen Z, Wang J, Wei H. Circ_0001178 regulates miR-382/VEGFA axis to facilitate hepatocellular carcinoma progression. Cell Signal 2020;72:109621. [PMID: 32240747 DOI: 10.1016/j.cellsig.2020.109621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
252 Wang J, He XD, Yao N, Liang WJ, Zhang YC. A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma. Can J Gastroenterol 2013;27:351-63. [PMID: 23781519 DOI: 10.1155/2013/417894] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
253 Yang Z, Duan J, Wang J, Liu Q, Shang R, Yang X, Lu P, Xia C, Wang L, Dou K. Superparamagnetic iron oxide nanoparticles modified with polyethylenimine and galactose for siRNA targeted delivery in hepatocellular carcinoma therapy. Int J Nanomedicine 2018;13:1851-65. [PMID: 29618926 DOI: 10.2147/IJN.S155537] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 6.3] [Reference Citation Analysis]
254 Qin G, Zhao C, Zhang L, Liu H, Quan Y, Chai L, Wu S, Wang X, Chen T. Dihydroartemisinin induces apoptosis preferentially via a Bim-mediated intrinsic pathway in hepatocarcinoma cells. Apoptosis 2015;20:1072-86. [PMID: 25935454 DOI: 10.1007/s10495-015-1132-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
255 Berasain C, Ujue Latasa M, Urtasun R, Goñi S, Elizalde M, Garcia-Irigoyen O, Azcona M, Prieto J, Avila MA. Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. Cancers (Basel) 2011;3:2444-61. [PMID: 24212818 DOI: 10.3390/cancers3022444] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
256 Kidner T, Dai M, Adusumilli PS, Fong Y. Advances in experimental and translational research in the treatment of hepatocellular carcinoma. Surg Oncol Clin N Am 2008;17:377-89, ix. [PMID: 18375358 DOI: 10.1016/j.soc.2008.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
257 Yang JC, Teng CF, Wu HC, Tsai HW, Chuang HC, Tsai TF, Hsu YH, Huang W, Wu LW, Su IJ. Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. Hepatology. 2009;49:1962-1971. [PMID: 19475690 DOI: 10.1002/hep.22889] [Cited by in Crossref: 79] [Cited by in F6Publishing: 84] [Article Influence: 6.1] [Reference Citation Analysis]
258 Welker MW, Trojan J. Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res 2013;5:337-47. [PMID: 24204170 DOI: 10.2147/CMAR.S35029] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
259 Huang TT, Yen MC, Lin CC, Weng TY, Chen YL, Lin CM, Lai MD. Skin delivery of short hairpin RNA of indoleamine 2,3 dioxygenase induces antitumor immunity against orthotopic and metastatic liver cancer. Cancer Sci 2011;102:2214-20. [PMID: 21899659 DOI: 10.1111/j.1349-7006.2011.02094.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
260 He L, Zhou X, Qu C, Hu L, Tang Y, Zhang Q, Liang M, Hong J. Musashi2 predicts poor prognosis and invasion in hepatocellular carcinoma by driving epithelial-mesenchymal transition. J Cell Mol Med. 2014;18:49-58. [PMID: 24305552 DOI: 10.1111/jcmm.12158] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 5.8] [Reference Citation Analysis]
261 Szyszko T, Brooks A, Tait P, Rubello D, Al-nahhas A. Therapy options for treatment of hepatic malignancy. Eur J Nucl Med Mol Imaging 2008;35:1824-6. [DOI: 10.1007/s00259-008-0798-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
262 Shigematsu S, Fukuda S, Nakayama H, Inoue H, Hiasa Y, Onji M, Higashiyama S. ZNF689 suppresses apoptosis of hepatocellular carcinoma cells through the down-regulation of Bcl-2 family members. Exp Cell Res. 2011;317:1851-1859. [PMID: 21624362 DOI: 10.1016/j.yexcr.2011.05.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
263 Huang B, Tian ZF, Li LF, Fan Y, Yin HY, Li Y, Mao Q, You ZL. LHX3 is an advanced-stage prognostic biomarker and metastatic oncogene in hepatocellular carcinoma. Cancer Biomark 2019;26:31-9. [PMID: 31306102 DOI: 10.3233/CBM-182257] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
264 Zhu AX, Raymond E. Early development of sunitinib in hepatocellular carcinoma. Expert Rev Anticancer Ther 2009;9:143-50. [PMID: 19105714 DOI: 10.1586/14737140.9.1.143] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
265 Huang P, Feng X, Zhao Z, Yang B, Fang T, Guo M, Xia J. p66Shc promotes HCC progression in the tumor microenvironment via STAT3 signaling. Experimental Cell Research 2019;383:111550. [DOI: 10.1016/j.yexcr.2019.111550] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
266 Chen M, Zhou X, Chen R, Wang J, Ye RD, Wang Y, Wu C, Mahato RI. Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy. Materials Today 2019;25:66-87. [DOI: 10.1016/j.mattod.2018.10.040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]